The auto injectors market made a total revenue of USD 1,011 million in 2023, and it will propel at a rate of 14.8% in the years to come, to touch a value of USD 2640.2 million in 2030.

The key factors powering the industry expansion include the mounting requirement for the drug administration ease, growing incidence of chronic and lifestyle associated diseases, and evolving healthcare technologies.

According to the WHO, over 16 billion injections are given on a yearly basis at a global level. So, the rising need for ease and safety throughout the procedure is powering the advance of the industry.

Disposable bio injector had the larger share credited to the lower risk of cross-contamination with these alternatives.

Particularly since the COVID-19, the requirement for disposable and single-use medical devices is on the rise to avert healthcare-related infections, a substantial burden for patients as well as the healthcare professionals. Moreover, utmost autoinjectors are at present obtainable as disposable devices, another reason for the larger share of this category.

The subcutaneous administration route is chosen over its intramuscular counterpart for the reason that the former guarantees longer drug obtainability in the body and its easier absorption. Furthermore, subcutaneous variants are precisely designed for home use, for example by individuals with mobility ailments and the aging.

North America is the leader of auto injectors market, and this prominent position will persist in the years to come as well. This is for the reason that the continent provides ready reimbursement for the use of autoinjectors. Furthermore, the growing occurrence of anaphylactic shock will encourage the acceptance of auto-injectors filled with epinephrine. Moreover, the two nations in the region exhibit a high awareness with regards to self-administration drug delivery devices.

The fastest growth is observed by the APAC region, chiefly as a result of the growing occurrence of diabetes. Since diabetics need normal insulin administration, auto-injectors save the trouble of seeing a medic every time and, therefore, make them independent.

Moreover, the mounting occurrence of severe reactions as a result of food allergies is driving the requirement for epinephrine injections.

Furthermore, the increasing elderly populace is powering the acceptance of home-based care. Seeing the prospects attained by a big patient base and initiatives of the government for making healthcare more available, auto-injector providers are putting efforts for marketing of their products in India, Japan, China, and other regional countries.

SOURCE: P&S Intelligence